Literature DB >> 22010278

Binding of kinetically inert metal ions to RNA: the case of platinum(II).

Erich G Chapman1, Alethia A Hostetter, Maire F Osborn, Amanda L Miller, Victoria J DeRose.   

Abstract

In this chapter several aspects of Pt(II) are highlighted that focus on the properties of Pt(II)-RNA adducts and the possibility that they influence RNA-based processes in cells. Cellular distribution of Pt(II) complexes results in significant platination of RNA, and localization studies find Pt(II) in the nucleus, nucleolus, and a distribution of other sites in cells. Treatment with Pt(II) compounds disrupts RNA-based processes including enzymatic processing, splicing, and translation, and this disruption may be indicative of structural changes to RNA or RNA-protein complexes. Several RNA-Pt(II) adducts have been characterized in vitro by biochemical and other methods. Evidence for Pt(II) binding in non-helical regions and for Pt(II) cross-linking of internal loops has been found. Although platinated sites have been identified, there currently exists very little in the way of detailed structural characterization of RNA-Pt(II) adducts. Some insight into the details of Pt(II) coordination to RNA, especially RNA helices, can be gained from DNA model systems. Many RNA structures, however, contain complex tertiary folds and common, purine-rich structural elements that present suitable Pt(II) nucleophiles in unique arrangements which may hold the potential for novel types of platinum-RNA adducts. Future research aimed at structural characterization of platinum-RNA adducts may provide further insights into platinum-nucleic acid binding motifs, and perhaps provide a rationale for the observed inhibition by Pt(II) complexes of splicing, translation, and enzymatic processing.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22010278      PMCID: PMC4080900          DOI: 10.1039/9781849732512-00347

Source DB:  PubMed          Journal:  Met Ions Life Sci        ISSN: 1559-0836


  102 in total

Review 1.  A guide to ions and RNA structure.

Authors:  David E Draper
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

2.  Mechanism of transcriptional stalling at cisplatin-damaged DNA.

Authors:  Gerke E Damsma; Aaron Alt; Florian Brueckner; Thomas Carell; Patrick Cramer
Journal:  Nat Struct Mol Biol       Date:  2007-11-11       Impact factor: 15.369

3.  Platination of the siRNA sense-strand modulates both efficacy and selectivity in vitro.

Authors:  Margareta Hägerlöf; Hanna Hedman; Sofi K C Elmroth
Journal:  Biochem Biophys Res Commun       Date:  2007-07-06       Impact factor: 3.575

4.  A new role for cisplatin: probing ribosomal RNA structure.

Authors:  Keshab Rijal; Christine S Chow
Journal:  Chem Commun (Camb)       Date:  2008-11-10       Impact factor: 6.222

5.  RNA polymerase II blockage by cisplatin-damaged DNA. Stability and polyubiquitylation of stalled polymerase.

Authors:  Yongwon Jung; Stephen J Lippard
Journal:  J Biol Chem       Date:  2005-11-07       Impact factor: 5.157

6.  Cisplatin inhibits protein synthesis in rabbit reticulocyte lysate by causing an arrest in elongation.

Authors:  K A Heminger; S D Hartson; J Rogers; R L Matts
Journal:  Arch Biochem Biophys       Date:  1997-08-01       Impact factor: 4.013

7.  Distribution of cisplatin in bone marrow cells: quantitative X-ray imaging.

Authors:  R G Kirk; M E Gates; C S Chang; P Lee
Journal:  Exp Mol Pathol       Date:  1995-08       Impact factor: 3.362

8.  RNA-selective modification by a platinum(II) complex conjugated to amino- and guanidinoglycosides.

Authors:  Jürgen Boer; Kenneth F Blount; Nathan W Luedtke; Lev Elson-Schwab; Yitzhak Tor
Journal:  Angew Chem Int Ed Engl       Date:  2005-01-28       Impact factor: 15.336

9.  Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.

Authors:  Goli Samimi; Roohangiz Safaei; Kuniyuki Katano; Alison K Holzer; Myriam Rochdi; Mika Tomioka; Murray Goodman; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

10.  Cisplatin inhibits in vitro translation by preventing the formation of complete initiation complex.

Authors:  J M Rosenberg; P H Sato
Journal:  Mol Pharmacol       Date:  1993-03       Impact factor: 4.436

View more
  6 in total

1.  RNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae.

Authors:  Alethia A Hostetter; Maire F Osborn; Victoria J DeRose
Journal:  ACS Chem Biol       Date:  2011-11-15       Impact factor: 5.100

2.  Base-Resolution Analysis of Cisplatin-DNA Adducts at the Genome Scale.

Authors:  Xiaoting Shu; Xushen Xiong; Jinghui Song; Chuan He; Chengqi Yi
Journal:  Angew Chem Int Ed Engl       Date:  2016-10-13       Impact factor: 15.336

3.  Mapping platinum adducts on yeast ribosomal RNA using high-throughput sequencing.

Authors:  Kory Plakos; Victoria J DeRose
Journal:  Chem Commun (Camb)       Date:  2017-11-28       Impact factor: 6.222

4.  Ascorbate sensitizes human osteosarcoma cells to the cytostatic effects of cisplatin.

Authors:  Naohiro Oka; Akiyoshi Komuro; Hisayuki Amano; Suman Dash; Masahiko Honda; Kazushige Ota; Shunji Nishimura; Takeshi Ueda; Masao Akagi; Hitoshi Okada
Journal:  Pharmacol Res Perspect       Date:  2020-08

5.  Nano-scale imaging of dual stable isotope labeled oxaliplatin in human colon cancer cells reveals the nucleolus as a putative node for therapeutic effect.

Authors:  Anton A Legin; Arno Schintlmeister; Nadine S Sommerfeld; Margret Eckhard; Sarah Theiner; Siegfried Reipert; Daniel Strohhofer; Michael A Jakupec; Mathea S Galanski; Michael Wagner; Bernhard K Keppler
Journal:  Nanoscale Adv       Date:  2020-11-26

6.  Insights into RNA binding by the anticancer drug cisplatin from the crystal structure of cisplatin-modified ribosome.

Authors:  Sergey V Melnikov; Dieter Söll; Thomas A Steitz; Yury S Polikanov
Journal:  Nucleic Acids Res       Date:  2016-04-13       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.